通过GSTM1基因定型优化拉泽提尼布治疗:减少过度药物暴露和潜在毒性的策略
Rob Ter Heine1, Bianca J C van den Bosch2, Robin M van Geel3
1Department of Pharmacy, Pharmacology & Toxicology Radboudumc, Geert Grooteplein Zuid 10, 6525GA, Nijmegen, The Netherlands. r.terheine@radboudumc.nl.
Cancer chemotherapy and pharmacology
|November 6, 2025
概括
根据GSTM1遗传状态,针对EGFR突变非小细胞肺癌的拉泽提尼布剂量个性化可以优化药物暴露. 这种方法旨在减少毒性和医疗保健成本,而不会影响治疗疗效.
科学领域:
- 药物基因组学 药物基因组学
- 在瘤学瘤学.
- 药物新陈代谢 药物新陈代谢
背景情况:
- 拉泽提尼布和阿米万塔马布组合在EGFR突变的NSCLC中显示出希望,但具有高毒性和成本.
- GSTM1遗传多态性显著影响拉泽提尼布暴露,零个体经历更高的全身药物水平.
- 目前固定的拉泽提尼布剂量不考虑GSTM1状态,可能导致不必要的毒性.
研究的目的:
- 开发和评估适合个体GSTM1遗传状态的替代拉泽提尼布剂量方案.
- 为了减轻毒性和减少与NSCLC患者的拉泽提尼布治疗相关的医疗保健费用.
主要方法:
- 利用基于经过验证的种群药理动力学模型的药理动力学模拟.
- 评估基因型导向剂量策略,专门针对GSTM1无个体.
主要成果:
- 预计两种替代方案 (160毫克QD和240毫克每隔一天) 可以在非零个体中实现与标准剂量相比的或更高的系统性拉泽提尼布暴露.
- 在GSTM1无患者中,160毫克的QD疗法显示GMR为1.43 (Ctrough) 和1.19 (Caverage).
- 240毫克每隔一天的治疗方案显示GMR为0.90 (Ctrough) 和0.89 (Caverage),每年每名患者的潜在成本节省高达50%.
结论:
- 基于GSTM1状态的个性化拉泽提尼布剂量是可行的.
- 这种药物基因组方法可以降低药物毒性和医疗保健成本.
- 通过量身定制的剂量方案,可以保持有效的拉泽提尼布暴露.
更多相关视频
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
412
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.5K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K